Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain from October 23-27, 2026. Poster Presentation Title: Part 2 Cohort Expansion of a Phase I Study of PLN-101095, a Dual αvβ8/αvβ1 Integrin In ...